COMMUNIQUÉS West-GlobeNewswire

National PKU Alliance Grant Advances Engineered Native Bacteria Candidate for Phenylketonuria (PKU)
16/10/2025
San Diego, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Endure Biotherapeutics, Inc. (Endure Bio®), a pioneer in engineered engraftable microbial therapeutics, today announced that its founding discovery laboratory at the [...]
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
16/10/2025
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will [...]
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
16/10/2025
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Verano Elevates Expanding Vape Product Portfolio with Exclusive, First-to-Market Launch of Revolutionary HYPHEN System
16/10/2025
HYPHEN features brand new best-in-class technology that allows consumers to flex between extracts, size formats and brands through interchangeable vape pods CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Verano Holdings [...]
Conavi Medical to Present at the Planet MicroCap Showcase: TORONTO in partnership with MicroCapClub on Wednesday, October 22, 2025
16/10/2025
TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing [...]
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
16/10/2025
CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
16/10/2025
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated [...]
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
16/10/2025
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with [...]
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
16/10/2025
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International Conference Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher [...]
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
16/10/2025
CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that on October 15, 2025, it [...]
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
16/10/2025
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc [...]
Belite Bio to Participate in the 2025 Maxim Growth Summit
16/10/2025
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal [...]
Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
16/10/2025
Clinical validation from the Busch Center highlights the proven, scalable innovation driving a paradigm shift in prostate care — delivering precision treatment and better patient outcomes TORONTO, Oct. 16, 2025 (GLOBE [...]
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
16/10/2025
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF and APRIL validated [...]
PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics
16/10/2025
MINNEAPOLIS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW) and an emerging biomedical device company focused on the [...]
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
16/10/2025
Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious [...]
Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland
16/10/2025
FORT MILL, S.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company and a leading developer of innovative solutions for cardiac procedures, is pleased to [...]
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
16/10/2025
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
16/10/2025
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observed Multi-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 ( [...]

Pages